Introduction
============

Alzheimer disease (AD) is a late onset neurodegenerative disorder characterized by progressive neuronal loss, especially in the cortex and the hippocampus ([@b30]). The vast majority of AD is sporadic (SAD), but mutations in the amyloid precursor protein (APP) and in presenilin-1 (PS1) and -2 (PS2), which are components of the γ-secretase complex that processes APP to produce amyloid-β (Aβ), have been identified in the familial form (FAD), which is similar to SAD but has an earlier age of onset. To date, there is no unifying hypothesis that can explain the diverse and apparently unrelated morphological and biochemical abnormalities---extracellular plaques containing Aβ fibrils ([@b71]), intracellular tangles containing hyperphosphorylated forms of the microtubule-associated protein tau ([@b71]), elevated serum cholesterol ([@b86]), altered phospholipid metabolism ([@b103]; [@b70]), aberrant calcium homeostasis ([@b5]), and mitochondrial dysfunction ([@b102])---detected in tissues and in cultured cells from AD patients ([@b71]), with no apparent direct link among them.

In the case of FAD, investigations into a common source of these apparently unrelated features have been complicated by uncertainty regarding the subcellular distribution of the presenilins. PS1 and PS2 have been located to numerous subcellular compartments, including endoplasmic reticulum (ER) ([@b2]), Golgi ([@b2]), plasma membrane (PM) ([@b57]), nuclear envelope ([@b46]), endosomes ([@b99]), lysosomes ([@b68]), and mitochondria ([@b1]). On the other hand, it is generally accepted that APP ([@b48]), presenilins, Aβ, and γ-secretase activity are enriched in lipid rafts (LRs) ([@b94]; [@b98]), which are specialized domains rich in cholesterol and sphingolipids that form detergent-insoluble aggregates in cell membranes (i.e., detergent-resistant membranes, or DRMs) ([@b84]). These regions have a liquid-ordered structure with unique biophysical characteristics that differs from the rest of the cell\'s liquid-disordered membranes ([@b84]). Traditionally, LRs have been considered to be present only in the PM ([@b84]). However, γ-secretase activity is negligible in this compartment, forming the basis of what has been called 'the spatial paradox\' ([@b18]). Recent evidence, however, has in fact indicated the existence of intracellular LRs/DRMs that are different in protein composition from those in the PM ([@b6]).

We recently found that PS1, PS2, APP, and γ-secretase activity are not homogeneously distributed in the ER, but rather are enriched in mitochondria-associated ER membranes (ER-MAMs or MAMs) ([@b3]). MAM is a dynamic subcompartment of the ER connected physically and biochemically to mitochondria that is involved in a number of key metabolic functions ([@b36]), including cholesterol metabolism ([@b78]), the synthesis and transfer of phospholipids between the ER and mitochondria ([@b96]), and calcium homeostasis ([@b17]).

We now report that MAM is a complex elaboration of the ER with the characteristics of an LR. Moreover, using a number of relevant tissues and cell lines ([Supplementary Table S1](#S1){ref-type="supplementary-material"}), we show that mutations in presenilins perturb MAM function significantly, and that these perturbations are also present in cells from FAD patients with mutations in PS1, PS2, and APP, and in SAD patients with no known genetic aetiology. These findings may shed new light on the biology of presenilins and on our understanding of some of the features associated with the pathogenesis of AD.

Results
=======

*MAM displays the characteristics of an intracellular* LR
---------------------------------------------------------

MAM is a dynamic domain of the ER responsible for the integration of several cellular functions, including Ca^2+^ signalling, lipid transport, energy metabolism, and cellular survival. For this reason, we speculated that MAM might have the characteristics of an LR/DRM in order for it to recruit and orientate the different signalling proteins needed for cellular homeostasis and for the effective cross-talk between mitochondria and ER ([@b35]; [@b109]; [@b26]). In addition, the fact that γ-secretase activity is present in LRs ([@b98]) and is also enriched in MAM ([@b3]) provided indirect support for the idea that MAM could be an LR/DRM.

We therefore incubated purified MAM from mouse tissues ([@b3]; [Supplementary Figure S1](#S1){ref-type="supplementary-material"}) with and without Triton X-100 (TX100), and loaded both samples onto a Percoll gradient under the same conditions used for its initial isolation. The TX100-treated MAM sample was fundamentally intact and migrated to the identical position in the gradient as did the untreated sample, consistent with the behaviour of a DRM ([Figure 1A](#f1){ref-type="fig"}). To separate LR from other cell contents, we loaded TX100-treated and untreated control MAM from mouse brain onto a sucrose gradient, and analysed fractions for the known MAM markers Pemt (phosphatidylethanolamine *N*-methyltransferase; [@b95]), Vdac1 (voltage-dependent anion channel 1; [@b36]), and Ps1 ([@b3]; [Figure 1B](#f1){ref-type="fig"}). The proteins migrated at similar positions in the lower density fractions, and were unaffected by detergent treatment ([Figure 1B](#f1){ref-type="fig"}), consistent with the behaviour of MAM as a DRM. By contrast, purified mitochondria and bulk ER from the bottom of the gradient behaved like detergent-soluble fractions ([Supplementary Figure S2](#S1){ref-type="supplementary-material"}), indicating the absence of DRMs in these organelles, as expected ([@b108]). MAM was not contaminated with PM rafts, as Src, a marker for PM rafts ([@b62]), was observable in sucrose gradient fractions from purified PM, but not from the crude mitochondrial fraction from which the MAM fraction was derived ([Figure 1C](#f1){ref-type="fig"}). Moreover, the cholesterol content of MAM was higher than that found in the cytoplasm, mitochondria, bulk ER, and total PM, and was comparable to that of LR from PM ([@b84]; [Figure 2A](#f2){ref-type="fig"}). These results are consistent with the numerous reports showing that presenilins and γ-secretase activity reside in LRs and suggest that MAM is an intracellular LR-like domain that may recruit and orient various signalling proteins needed to regulate cross-talk between ER and mitochondria.

Elevated cholesteryl ester synthesis in PS-mutant cells and AD patient fibroblasts
----------------------------------------------------------------------------------

Given that MAM is an LR/DRM, the regulation of cholesterol metabolism should be an important determinant of its structure and function. Acyl-CoA:cholesterol acyltransferase (ACAT), which catalyses the conversion of free cholesterol to cholesteryl esters (CE) and controls the equilibrium between membrane-bound free cholesterol and CE stored in cytoplasmic lipid droplets ([@b75]), is enriched in MAM ([@b78]). We confirmed that MAM is indeed the predominant locus for CE synthesis, as ACAT protein was not only more abundant in MAM as compared to bulk ER and mitochondria ([Figure 2B](#f2){ref-type="fig"}, inset), but also had an ∼3-fold higher enzymatic activity ([Figure 2B](#f2){ref-type="fig"}).

Using CE synthesis as a probe of MAM function, we determined the role of presenilins in this process by analysing mouse embryonic fibroblasts (MEFs) lacking Ps1 (Ps1-KO), Ps2 (Ps2-KO), or both proteins (DKO). Compared to wild-type (WT) MEFs, the mutant lines showed increased steady-state levels of total ([@b32]) and free cholesterol ([Figure 2C](#f2){ref-type="fig"}), but more importantly, the relative differences in CE content were even greater, with up to ∼5-fold more CE in DKO than in WT MEFs ([Figure 2C](#f2){ref-type="fig"}). Upon labelling the cells with ^3^H-cholesterol to monitor its conversion by ACAT into ^3^H-cholesteryl esters, we found significantly higher ACAT activity in the Ps-mutant MEFs (up to ∼2.5-fold over controls) ([Figure 2D](#f2){ref-type="fig"}). Both presenilin isoforms contributed to CE synthesis, as the average increase in CE content was far more pronounced in the Ps1+Ps2 DKO MEFs (145% greater than WT) than in either individual knockout alone (96 and 63% greater than WT in Ps1- and Ps2-KO, respectively) ([Figure 2D](#f2){ref-type="fig"}). In a control experiment, we determined that this upregulation was not due to an increase in *Acat1* expression ([Supplementary Figure S3](#S1){ref-type="supplementary-material"}). Because CE synthesis in the Ps1-KO cells was higher than in the Ps2-KOs, and because PS1 plays a more significant role in FAD than does PS2 ([@b44]), we also examined CE synthesis in immortalized mouse MEFs in which Ps1 expression had been knocked down (Ps1-KD) ([Supplementary Figure S4](#S1){ref-type="supplementary-material"}). There was an ∼3-fold increase in the kinetics of CE formation in Ps1-KD cells versus control ([Figure 2E](#f2){ref-type="fig"}). Notably, we detected significant increases in CE synthesis in PS-mutant FAD cells (∼1.8-fold higher than controls), and equally strikingly, in SAD cells as well (∼1.7-fold higher) ([Figure 2F](#f2){ref-type="fig"}).

Consistent with the increase in CE, we observed numerous structures that appeared to be lipid droplets in electron microscopic images of DKO, but not control, MEFs (asterisks in [Figure 3A](#f3){ref-type="fig"}). We therefore looked for the presence of lipid droplets after staining cells with HCS LipidTox Green^TM^ ([Figure 3B](#f3){ref-type="fig"}) and Oil Red O ([Supplementary Figure S5](#S1){ref-type="supplementary-material"}). Whereas the LipidTox stain in WT MEFs was diffuse, the PS-mutant MEFs contained numerous discrete LipidTox-positive droplets (∼5-fold greater signal) ([Figure 3B](#f3){ref-type="fig"}; see also [Supplementary Figure S6](#S1){ref-type="supplementary-material"}). Similar results were also obtained with the Ps1-KD cells ([Figure 3C](#f3){ref-type="fig"}); importantly, the increase in lipid droplets in Ps1-KD cells (∼5-fold over control) was rescued by overexpression of human WT PS1, but not of human PS1 harbouring the A246E mutation found in many FAD patients ([Figure 3C](#f3){ref-type="fig"}). Notably, we detected significantly more lipid droplets in fibroblasts from FAD patients (with mutations in PS1, PS2, and APP) and in SAD fibroblasts (an average of ∼20--30% of the cells was LipidTox positive) versus controls (∼3% positive) ([Figure 3D](#f3){ref-type="fig"}; [Supplementary Figures S5 and S6](#S1){ref-type="supplementary-material"}). These observations may help explain the elevated numbers of lipids droplets found in fibroblasts ([@b66]) and neurons ([@b31]) of SAD patients.

Taken together, the data indicate that MAM activity, as measured by CE synthesis, is altered in AD, and that presenilins and APP, and perhaps also γ-secretase activity, may play a key role in regulating MAM function.

Elevated phospholipid synthesis in PS-mutant cells and AD patient fibroblasts
-----------------------------------------------------------------------------

It is well known that ER--mitochondrial communication via MAM is necessary for phospholipid synthesis ([@b100]). Phosphatidylserine (PtdSer) is synthesized in the MAM ([@b36]); it then translocates to mitochondria, where it is converted to phosphatidylethanolamine (PtdEtn); PtdEtn then translocates back to the MAM, where it is methylated (by PEMT) ([@b97]) to generate phosphatidylcholine (PtdCho). The trafficking of these phospholipids between ER and mitochondria is a recognized measure of the communication between both organelles and of the regulation of MAM function ([@b100]). Therefore, to test directly the role of presenilins in ER--mitochondrial communication, we incubated Ps-mutant MEFs in medium containing ^3^H-serine (^3^H-Ser) and measured the incorporation of the label into newly synthesized ^3^H-PtdSer and ^3^H-PtdEtn. The levels of both labelled species increased \>3-fold in the DKO MEFs as compared to WT ([Figure 4A](#f4){ref-type="fig"}), suggesting an upregulation of MAM function and of ER--mitochondrial cross-talk in these cells. In a control experiment, we determined that this upregulation was not due to an increase in the expression of *Ptdss1*, *Ptdss2*, or *Pisd*, three key genes involved in transport of phospholipids between ER and mitochondria ([Supplementary Figure S3](#S1){ref-type="supplementary-material"}).

To determine the kinetics of this upregulation, we performed pulse-chase analysis by incubating the MEFs with ^3^H-Ser for 1 h, followed by a chase with cold serine for various time periods ([Figure 4B](#f4){ref-type="fig"}). The incorporation of label into ^3^H-PtdSer during the pulse (time 0 in [Figure 4B](#f4){ref-type="fig"}) was significantly higher in the Ps1-KO and DKO MEFs than in control. During the chase, the amount of ^3^H-PtdSer decreased and that of ^3^H-PtdEtn increased, consistent with the conversion of the former into the latter, with higher rates in the Ps1-KO and DKO MEFs (up to three-fold higher). While the increase in lipid synthesis in the pulse-chase was not altered significantly in the Ps2-KO MEFs, Ps2 clearly contributes to phospholipid metabolism and MAM function, as lipid synthesis in the Ps1+Ps2 double knockout was much more pronounced than in the Ps1-knockout alone ([Figure 4B](#f4){ref-type="fig"}). These results were confirmed in isolated MEF crude mitochondrial fractions (containing essentially only ER, MAM, and mitochondria; [@b3]) ([Figure 4C](#f4){ref-type="fig"}). The rate of phospholipid synthesis was also increased in Ps1-KD cells ([Figure 4D](#f4){ref-type="fig"}) and, importantly, in FAD and SAD fibroblasts (by ∼1.5- to 2-fold over controls) ([Figure 4E](#f4){ref-type="fig"}).

Since some of the PtdEtn synthesized is exported to the inner leaflet of the PM ([@b97]), we hypothesized that it would be elevated in the PM of mutant cells. Accordingly, we treated cells with two highly related antibiotics, cinnamycin (Cin; also called Ro09-0198) ([@b16]) and duramycin (Dura) ([@b58]), both of which are 19-aa cyclic peptides that form a complex specifically with PtdEtn to induce pore formation in the PM in a PtdEtn concentration-dependent manner, followed by rapid cell death ([@b54]) (see example in [Figure 5A](#f5){ref-type="fig"}, left and middle panels). Ps1-KO and DKO MEFs were ∼3.5-fold more Cin sensitive than were controls ([Figure 5A](#f5){ref-type="fig"}, right panel). Similarly, Ps1-KD cells were ∼3-fold more Cin sensitive than were controls; as before, this sensitivity could be rescued by overexpression of human WT, but not A246E mutant, PS1 ([Figure 5B](#f5){ref-type="fig"}, left panel). Notably, FAD and SAD cells were significantly (∼3- to 5-fold) more Cin sensitive than were controls ([Figure 5B](#f5){ref-type="fig"}, right panel). We also were able to visualize the presence of PtdEtn on the cell surface by staining cells with FL-SA-Ro ([Figure 5C](#f5){ref-type="fig"}), a fluorescent-conjugated form of cinnamycin that binds to PtdEtn on the PM but does not initiate cell death ([@b23]). In agreement with the Cin-sensitivity results, ∼4 times as many FAD and SAD cells were stained with FL-SA-Ro as compared to controls ([Figure 5C](#f5){ref-type="fig"}; [Supplementary Figure S7](#S1){ref-type="supplementary-material"}).

Together with the CE data, these results point to an upregulation of MAM function in AD, either by mutations in presenilins or APP or, in the case of SAD, by unknown causes.

*Increased ER*--*mitochondrial contacts in PS-mutant cells and AD patient fibroblasts*
--------------------------------------------------------------------------------------

The increased biochemical activity of MAM in PS-mutant cells prompted us to see if ER--mitochondrial contacts were physically altered. We therefore transfected cells with DsRed-Mito to detect mitochondria (in red) and with GFP-Sec61β to detect ER (in green), and used confocal microscopy and Image J analysis to detect and quantitate regions where the two signals were in close apposition (see example in [Figure 6A](#f6){ref-type="fig"}). Using this method, we found that the degree of ER--mitochondrial apposition was significantly higher in Ps1-KO (∼34±10% of the total signal), Ps2-KO (34±6%), and DKO (56±6%) MEFS than in WT MEFS (12±4%) ([Figure 6B](#f6){ref-type="fig"}, left). Moreover, the degree of apposition was significantly higher in fibroblasts from both FAD (26±4%) and SAD (24±6%) patients than in those from controls (11±2%) ([Figure 6B](#f6){ref-type="fig"}, right).

In order to observe ER--mitochondrial apposition at higher resolution, we imaged MEFs and patient cells by electron microscopy (EM). We observed a significant increase in the length of mitochondrial-ER contacts (i.e., MAM) in DKO as compared to WT MEFs ([Figure 7](#f7){ref-type="fig"}). Specifically, there were significantly more numerous 'long\' (50--200 nm; [Figure 7C](#f7){ref-type="fig"}) and 'very long\' (\>200 nm; [Figure 7E](#f7){ref-type="fig"}) contacts in DKO MEFs than in WT MEFs (∼5-fold and \>10-fold, respectively; [Figure 7F](#f7){ref-type="fig"}, left), whereas connections in WT MEFs were much shorter and more 'punctate\' (\<50 nm; [Figure 7B](#f7){ref-type="fig"}). We found a similar increase in 'long\' and 'very long\' contacts in AD patients ([Figure 7F](#f7){ref-type="fig"}, right; [Supplementary Figure S8](#S1){ref-type="supplementary-material"}). Thus, the increased biochemical activity of MAM in PS-mutant and in AD cells correlated with an increased area of physical association between the two organelles.

*Analysis of MAM function in cells deficient in ER*--*mitochondrial communication*
----------------------------------------------------------------------------------

If upregulated MAM function in PS-mutant and AD cells is related to increased ER--mitochondrial communication, then decreased contacts between the two organelles should have an opposite effect. We therefore assayed cholesterol ester and phospholipid synthesis in MEFs lacking mitofusin-2 (Mfn2), a protein that is required for MAM-mediated ER--mitochondrial interactions ([@b19]). In agreement with our hypothesis, we found an ∼2-fold lower rate of CE synthesis in Mfn2-KO MEFs ([Figure 8A](#f8){ref-type="fig"}), and an ∼25% decrease in phospholipid synthesis and transport, as compared to WT MEFs ([Figure 8B](#f8){ref-type="fig"}). Finally, we asked whether the deficient ER--mitochondrial communication present in Mfn2-KO cells affected γ-secretase activity. We measured the levels of APP and its C-terminal cleavage products C99 and AICD (APP intracellular domain) ([@b3]; [@b24]) (see scheme in [Figure 8C](#f8){ref-type="fig"}). There was an ∼2-fold reduction in the amount of AICD in Mfn2-KO cells as compared to WT, and a concomitant increase in C99 ([Figure 8C](#f8){ref-type="fig"}). As a control, we also measured these three proteins in WT and DKO MEFs. As expected, no AICD was produced in the DKO cells ([@b3]), while C99 accumulated accordingly ([Figure 8C](#f8){ref-type="fig"}). Importantly, the reduction in γ-secretase activity in Mfn2-KO cells was not due to a relocalization or mislocalization of presenilins in these cells, as they were still highly enriched in the MAM compartment ([Figure 8D](#f8){ref-type="fig"}). Thus, the deficiency in γ-secretase activity in Mfn2-KO cells supports the view that ER--mitochondrial communication is required for this functionality.

Given that mutations in presenilins increase both MAM function and ER--mitochondrial connectivity, whereas mutations in Mfn2 decrease the latter ([@b19]), we asked if one could complement the other. Accordingly, we knocked down *Ps1* and *Ps2* transcripts simultaneously by ∼80% in WT and Mfn2-KO MEFs ([Supplementary Figure S9A](#S1){ref-type="supplementary-material"}), and measured phospholipid synthesis. We found that the decreased production of ^3^H-PtdSer and ^3^H-PtdEtn in Mfn2-KO MEFs was reversed when *Ps1/2* expression was knocked down ([Figure 9A](#f9){ref-type="fig"}, left panel). Conversely, when we knocked down *Mfn2* transcripts in WT and Ps1/2-DKO MEFs by ∼80% ([Supplementary Figure S9B](#S1){ref-type="supplementary-material"}), we obtained the opposite result, as the increased phospholipid synthesis in the DKO MEFs was significantly reduced upon knocking down *Mfn2* expression ([Figure 9A](#f9){ref-type="fig"}, right panel); notably, the phospholipid transport data correlated with the degree of ER--mitochondrial colocalization in these cells ([Figure 9B](#f9){ref-type="fig"}). Analysis of the cells for duramycin sensitivity confirmed the biochemical findings, especially in the Ps1/2-DKO cells, where knockdown of *Mfn2* blunted the increase in Dura sensitivity relative to that in WT MEFs ([Figure 9C](#f9){ref-type="fig"}). Finally, we measured CE synthesis (as assayed by LipidTox staining) and found that the increase in lipid droplet formation seen in Ps1/2-DKO MEFs was reversed by *Mfn2* silencing ([Figure 9D](#f9){ref-type="fig"}).

Taken together, these results imply that presenilins and Mfn2 may affect the same pathway to regulate MAM activity and the apposition of ER to mitochondria.

Analysis of MAM function in cells deficient in γ-secretase activity
-------------------------------------------------------------------

Our data clearly show that mutations in presenilins affect MAM function and ER--mitochondrial connectivity, but it was unclear whether the enzymatic activity of γ-secretase plays a direct role in these processes. Accordingly, we examined HeLa cells in which PS1 expression had been knocked down by shRNA ([Supplementary Figure S9C](#S1){ref-type="supplementary-material"}) and asked if we could rescue MAM function by overexpressing either PS1-WT or a 'catalytically dead\' construct encoding a D385A mutation in PS1 ([@b105]). Whereas adding back the WT version of PS1 rescued the knockdown phenotype, as expected, cells transfected with the D385A mutant showed an increase in ER--mitochondrial communication and MAM activity (as measured by phospholipid synthesis and lipid droplet formation; [Supplementary Figure S10](#S1){ref-type="supplementary-material"}), similar to the increase observed in the PS1 knockdown MEFs ([Figure 3C](#f3){ref-type="fig"}). The failure of 'catalytically dead\' PS1 to rescue the knockdown phenotypes would suggest that γ-secretase activity itself is responsible for the regulation of MAM activity. However, it has been shown that full-length PS1 containing the D385A mutation cannot be cleaved into the N- and C-terminal fragments required for γ-secretase activity ([@b105]; [@b45]); this cleavage defect may also affect the proper subcellular localization of the protein ([@b13]). Moreover, PS1-D385A has been shown to depress the activity of WT PS1, in a dose-dependent manner ([@b45]), as well as to compete with WT PS1 for limiting factors required for γ-secretase activity ([@b91]). For these reasons, we believe that overexpressing the D385A mutant basically mimics the KO/KD phenotype ([@b15]), and therefore does not really answer the question as to whether γ-secretase activity itself regulates ER--mitochondrial communication and/or MAM function.

We therefore took a more direct biochemical approach. We treated various cell types with DAPT ((*N*-\[*N*-(3,5-difluorophenacetyl)-[L]{.smallcaps}-alanyl\]-S-phenylglycine t-butyl ester)), a highly specific γ-secretase inhibitor ([@b61]), for 24 h ([Supplementary Figure S9D](#S1){ref-type="supplementary-material"}), and then assayed them for MAM function. DAPT had a profound effect on CE synthesis, as measured by the detection of lipid droplets, with an increase in the % of LipidTox-positive cells ranging from ∼2-fold in MEFs to ∼7-fold in 3T3 and HeLa cells ([Figure 10A](#f10){ref-type="fig"}). Surprisingly, however, the increase in phospholipid transport was much lower (only on the order of ∼20%; [Figure 10B](#f10){ref-type="fig"}), a value far lower than the robust increases in phospholipid transport that were detected in cells (including MEFs) harbouring presenilin mutations (see [Figure 4](#f4){ref-type="fig"}). We therefore quantitated the amount of ER--mitochondrial colocalization (performed as in [Figure 6](#f6){ref-type="fig"}) in these DAPT-treated cells, and found that the drug had essentially no effect on the degree of ER--mitochondrial apposition ([Figure 10C](#f10){ref-type="fig"}).

Taken together, these data imply that the catalytic activity of γ-secretase can have significant effects on MAM function (at least with respect to cholesterol ester synthesis) but appears to have little effect on establishing ER--mitochondrial connectivity. They also point to the possibility that there may be two separate classes of functions at the ER--mitochondrial interface: those required for 'horizontal\' activity (i.e., intraorganellar enzymatic functions residing within the MAM compartment itself, as measured, for example, by CE synthesis) and those required to maintain 'vertical\' MAM activity (i.e., interorganellar communication between ER and mitochondria, as measured, for example, by phospholipid transport).

Discussion
==========

We previously showed that MAM is the predominant subcellular locus for presenilins and for γ-secretase activity ([@b3]). We now show that mutations in PS1, PS2, and APP can upregulate MAM function and increase ER--mitochondrial connectivity significantly, implying that presenilins are negative regulators of these behaviours. Moreover, we found that cells from patients with SAD, in which PS1, PS2, and APP structure (but perhaps not expression; [@b60]; [@b80]) are normal, also display the same hallmarks of upregulated MAM function and ER--mitochondrial communication as do those with FAD.

Because MAM dysfunction is the common denominator underlying the phenotypes seen in both FAD and SAD, we therefore propose that increased MAM activity and ER--mitochondrial communication lies at the heart of AD pathogenesis ([Figure 11](#f11){ref-type="fig"}). In support of this view, we note that many of the biochemical and morphological phenotypes associated with AD---altered cholesterol, phospholipid, glucose, and calcium metabolism, aberrant mitochondrial behaviour and function, and notably, altered Aβ production---are the very functions that are associated with MAM and with connections between ER and mitochondria.

The first clue that MAM might be involved in AD came from the observation that presenilins and γ-secretase activity are enriched in MAM ([@b3]). This speculation was reinforced by the finding that MAM is an LR-like domain ([Figure 1](#f1){ref-type="fig"}; [@b35]; [@b109]; [@b26]), which is consistent with previous data showing that APP processing to produce Aβ depends on LRs ([@b22]; [@b94]; [@b98]; [@b48]; [@b65]). Apart from the lack of appropriate markers to detect MAM, one of the reasons that MAM was overlooked as a detergent-resistant membrane, and as the region in which PS\'s, APP, and γ-secretase activity are enriched, may be that most methods used to isolate rafts do not separate the PM from intracellular membranes ([@b53]). Thus, intracellular DRMs like MAM will be co-isolated with PM rafts during the subfractionation process, obscuring the localization of PS\'s and γ-secretase activity at ER--mitochondria connections. This ambiguity might help explain earlier observations indicating that, along with the presenilins, the other components of the γ-secretase complex---nicastrin, APH-1, and PEN-2---are not only present in the MAM ([@b3]) but are also enriched in DRMs ([@b98]).

Furthermore, the fact that MAM is a DRM may also help explain the lack of consensus regarding the subcellular localization of presenilins and γ-secretase activity, as detecting proteins embedded in DRMs can be technically challenging ([@b81]). It may also explain why MAM markers such as VDAC ([@b90]) and calnexin ([@b63]) were found in some studies of PM rafts ([@b25]; [@b108]) and why Aβ was reported to be present in mitochondria ([@b52]; [@b55]). Likewise, crude mitochondrial preparations contain MAM that can lead one into thinking that mitochondria contain *bona fide* LRs ([@b85]) when in fact they do not ([@b108]). It has long been known that presenilins, APP, Aβ, and γ-secretase activity are enriched in LRs/DRMs ([@b94]; [@b48]), but it had always been assumed that these rafts were located at the PM ([@b49]). Our data are consistent with an alternate interpretation, namely, that APP processing to produce Aβ occurs not at LRs in the PM, but intracellularly in the MAM ([@b35]). We note that several groups have suggested the existence of intracellular rafts in the ER or mitochondria ([@b6]); we believe that these LRs/DRMs are, in fact, MAMs ([@b35]; [@b109]; [@b26]).

As a locus for the integration of key cellular functions and signalling ([@b36]), MAM apparently requires a more rigid liquid-ordered phase to recruit, orient, regulate, and limit the lateral mobility of the membrane proteins within its boundaries, so as to promote the cross-talk of mitochondria and ER. If MAM is indeed an LR, then alterations in its structure and composition may affect profoundly the cellular functions localized within it. It is possible that the loss or alteration of γ-secretase activity (via, e.g., mutations in presenilins and APP in the case of FAD) affects the structure and lipid composition of cellular membranes in general and of MAM in particular, especially in AD ([@b10]). Conversely, alterations in MAM via, for example, disrupting Mfn2 expression, can also affect γ-secretase activity, with the physical distance separating ER from mitochondria playing a critical role in the regulation of MAM function ([@b17]). Thus, we believe that perturbations in ER--mitochondrial connectivity are the key element underlying AD pathogenesis, and perhaps other neurodegenerative diseases as well ([@b82]).

As noted above, many of the apparently unrelated cellular functions that are misregulated in AD can be ascribed to increased MAM function and ER--mitochondrial connectivity. First, it has long been known that AD patients have elevated ACAT levels ([@b66]), elevated cholesterol and/or CEs ([@b86]; [@b66]), and deposition of lipid droplets in peripheral cells ([@b67]; [@b56]) and in neurons ([@b31]). In addition, there is compelling evidence that MAM plays a role in lipid droplet formation ([@b101]) and that both PtdEtn synthesis ([@b65]) and ACAT activity ([@b75], [@b74]) are required for Aβ production. The connection of MAM-localized ACAT1 to AD is intriguing: the enzyme is absolutely required for the generation of Aβ, by modulating the equilibrium between free and esterified cholesterol ([@b75], [@b76], [@b74]; [@b72]), presumably as a result of its affects on APP processing ([@b42], [@b43]; [@b7]). While it is unclear how mutated presenilins affect Aβ production, it has been shown that pathogenic mutations in PS1 affect the conformation of the γ-secretase active site ([@b11]). Thus, one possibility is that altered cholesterol and lipid composition within the MAM membrane changes the orientation of APP and its cleavage by γ-secretase, and hence, the generation of total Aβ and an alteration in the ratio of Aβ~42~:Aβ~40~ ([@b93]; [@b40]). In support of this view, we note that the membrane thickness of LRs is greater than that of the surrounding bilayer ([@b77]; [@b51]), and that the thickness of model membranes affects the cleavage specificity of γ-secretase as well as the relative amounts of Aβ~40~ and Aβ~42~ ([@b104]). A connection between MAM and Aβ production is also supported by the recent finding that extracellular plaques have an intracellular origin, and that this process is mediated by sphingomyelin and GM1 gangliosides ([@b106]), both of which are components of MAM and which play a significant role in its regulation ([@b79]; [@b33], [@b34]). In addition, the finding of increased phospholipid synthesis in PS-mutant cells, indicative of increased cross-talk between ER and mitochondria ([@b100]), is consistent with the reported aberrations in phospholipid profiles in AD patients ([@b70]; [@b10]).

Alterations in MAM likely affect other cellular functions as well. One of the most critical of these is calcium homeostasis ([@b17]; [@b28]), as MAM is highly enriched in the sarco-ER calcium-ATPase ([@b20]), the sigma-1 receptor ([@b35]), ryanodine receptors (RyRs) ([@b27]), and inositol-1,4,5-trisphosphate receptors (IP3Rs) ([@b36]). Thus, increased ER--mitochondrial communication in AD could explain the altered intracellular Ca^2+^ trafficking via RyRs ([@b88]) and IP3Rs ([@b50]; [@b107]), leading to the aberrant calcium homeostasis found in AD patients ([@b5]). Surprisingly, [@b107] concluded that PS2, but not PS1, modulates ER--mitochondria interactions and calcium cross-talk, a finding that differs with the data reported here showing that *both* presenilin isoforms mediate MAM function and ER--mitochondrial communication; it also differs with the observation that mutations in PS1 enhance IP3R-mediated calcium trafficking ([@b14], [@b15]; [@b59]), which is clearly an MAM-mediated function ([@b36]). Their findings would also be difficult to reconcile with the fact that mutations in PS1 are more prevalent in FAD than are those in PS2, and result in a more 'severe\' clinical course ([@b44]), and would also imply that the mechanisms by which these two highly related proteins cause FAD are radically different, even though both proteins are components of the γ-secretase complex. However, we note that [@b107] relied on experiments in which the presenilin and multiple reporter constructs were overexpressed transiently, which may have introduced a degree of ambiguity in the interpretation of their data ([@b87]). In addition, these transfections were performed in cells expressing endogenous WT chromosomal PS1 and PS2 alleles, which could have resulted in potential feedback of the introduced constructs on their regulation, a potential problem that was circumvented in our experimental design, which relied instead on knockdown and knockout constructs and on AD patient cells expressing endogenous mutated alleles. We also note that, contrary to what we observed here, [@b107] found reductions in *Mfn2* expression upon knockdown of the presenilins; such reductions may have inadvertently masked any effect on MAM function due to reduced presenilin expression. Taken together, we believe that the conclusion of [@b107] that only PS2, and not PS1, affects MAM behaviour is open to question.

Mitochondrial dysfunction in AD has been reported extensively ([@b89]), but there is no clear evidence as to whether it is cause or effect. Altered connections between ER and mitochondria would almost certainly affect mitochondrial dynamics (e.g., shape, distribution, and movement; [@b47]) and function (e.g., oxidative energy metabolism, calcium buffering capacity, and free radical production; [@b69]; [@b38]; [@b29]; [@b8]), and thus may be the underlying cause of the reported aberrant mitochondrial phenotypes seen in AD ([@b89]).

Our assays of MAM function upon inhibition of γ-secretase activity yielded the surprising result that whereas the catalytic activity of the enzyme is required for at least some aspects of MAM function, it is apparently not required to maintain ER--mitochondrial connectivity. Together with the Mfn2 rescue experiments, this result, which was obtained in cells expressing endogenous WT presenilins, implies that the presenilin protein itself (and not just its proteolytic activity) is acting as a regulator of the distance between ER and mitochondria ([@b17]). A corollary of this finding is that the presenilins might play a role in ER--mitochondrial communication independent of their enzymatic function. These results also underscore the fact that MAM function and ER--mitochondrial communication are two separate aspects of this single cellular subdomain: on the one hand, MAM is a true compartment of the ER, with its own suite of biochemical activities, whereas on the other, it is a bridge that connects two organelles, namely the ER and the mitochondria. We note, however, that all of our data indicate that in AD, both aspects---MAM function and interorganellar distance---are affected, but whether both aspects must be affected consistently in order to cause disease remains to be determined.

Finally, our findings have implications for understanding the genetics of AD ([@b39]; [@b64]). Most presenilin mutations causing FAD are dominant and are presumed to cause a gain of function ([@b21]; [@b15]). However, the increased MAM function in PS-KD and -KO cells reported here imply that the effects of many (but probably not all; [@b12]) pathogenic PS1 mutations are more likely to be due to loss of function or to a gain of negative function ([@b60]; [@b4]; [@b83]; [@b37]; [@b44]; [@b9]).

We believe that the increased MAM function and ER--mitochondrial cross-talk found in all PS mutant cells analysed could help explain some of the features and early events in AD, such as elevated serum cholesterol levels, mitochondrial dysfunction, oxidative stress, and calcium deregulation ([@b81]), which are all upstream of the appearance of plaques and tangles ([@b73]) and which are detected routinely in AD patients. As such, upregulated MAM function could play a hitherto unrecognized and critical role in the pathogenesis of AD ([@b81]) that may help us to understand better this devastating disease.

Materials and methods
=====================

Cells and reagents
------------------

WT, Ps1-KO, Ps2-KO, and DKO mouse MEFs were gifts of Dr Bart De Strooper (University of Leuven). WT and Mfn2-KO MEFs were gifts of David Chan (California Institute of Technology). PS1- and APP-mutant FAD cells were kind gifts of Gary E Gibson (Cornell University) and Richard Cowburn (Karolinska Institute). Other AD and control cell lines were obtained from the Coriell Institute for Medical Research (Camden, NJ) (see [Supplementary Table S1](#S1){ref-type="supplementary-material"}). We used antibodies to PS1 (aa 1--65 (Calbiochem 529591) and aa 303--316 (Calbiochem PC267)), PEMT (a gift of Joan Vance, University of Alberta), VDAC1 (Abcam ab15895), ACAT1 (Abcam ab39327), Na^+^/K^+^-ATPase (Abcam ab7671), SRC tyrosine kinase (Abcam ab32102), NDUFA9 (monoclonal; Molecular Probes A21344), MFN2 (Abcam ab50838), and SSRα (a gift of Howard Worman and Martin Wiedemann, Columbia University). Thin layer chromatography (TLC) silica plates were from EMD Biosciences (5748-7). Phosphatidylserine (P7769), phosphatidylethanolamine (60648), cholesteryl palmitate (C6072), cholesteryl oleate (C9253), lipid markers for TLC (P3817), cinnamycin (C5241), duramycin (D3168), and DAPT (D5942) were from Sigma. Radiolabelled ^3^H-serine and ^3^H-cholesterol were from Perkin-Elmer; ^3^H-oleoyl-CoA was from Moravek Biochemicals (MT1649); and fatty acid-free bovine serum albumin (FAF-BSA) was from MP Biomedical (820472).

Subcellular fractionation and western blotting
----------------------------------------------

Purification of ER, MAM, and mitochondria was performed and analysed as described ([@b3]).

Isolation of LRs
----------------

To identify detergent-resistant domains, samples were resuspended in 400 μl of isolation buffer (IB: 250 mM mannitol, 5 mM HEPES pH 7.4, and 0.5 mM EGTA) containing 1% Triton X-100 and incubated at 4°C with rotation for 1 h. Samples were adjusted to 80% sucrose, placed at the bottom of a 5--30% sucrose gradient, and centrifuged at 250 000 *g* for 18 h. After fractionation, equal volumes of each fraction were loaded on an SDS--PAGE gel and analysed by western blot.

Measurement of cholesterol species
----------------------------------

Quantification of total cholesterol and CEs was performed using the Cholesterol/Cholesteryl Ester Quantitation kit from Calbiochem (428901).

Lipid droplet staining
----------------------

Staining of lipid droplets was performed using HCS LipidTox™ Deep Green neutral lipid stain (Invitrogen H34475) according to manufacturer\'s instructions. Lipid droplet staining was quantified using ImageJ. When reported as intensities, the values in the text represent the product of the intensity and the area covered by the fluorescent signal above background in every cell examined. For each cell type and/or condition, we took between 15 and 20 images for analysis. The images were first taken at lower magnification (× 20) in order to view 50--100 cells per field. The numbers reported in the text represent the averages derived from the quantification of staining in 500--600 cells.

For lipid droplet staining by Oil Red O, we first prepared a stock solution (35% Oil Red O in isopropanol), stirring the mix for 12 h and filtering it before use. Cultured cells were fixed in 10% formalin in PBS for at least 1 h and washed twice in ddH~2~O. The plates were incubated in 60% isopropanol for 5 min at RT, the alcohol was discarded, and the cells were allowed to dry completely at RT. One microlitre of a filtered Oil Red O working solution (60% stock solution in H~2~O) was added to the cells at RT for 10 min. The Oil Red O solution was removed and the samples were immediately washed in ddH~2~O before acquiring images under the microscope.

Analysis of phospholipid synthesis in cultured cells
----------------------------------------------------

Cells were incubated for 2 h with serum-free medium to ensure removal of exogenous lipids. The medium was then replaced with MEM containing 2.5 μCi/ml of ^3^H-serine for the indicated periods of time. The cells were washed and collected in DPBS, pelleted at 2500 *g* for 5 min at 4°C, and resuspended in 0.5 ml water, removing a small aliquot for protein quantification. Lipid extraction was done by the Folch method. Briefly, three volumes of chloroform/methanol 2:1 were added to the samples and vortexed. After centrifugation at 8000 *g* for 5 min, the organic phase was washed twice with two volumes of methanol/water 1:1, and the organic phase was blown to dryness under nitrogen. Dried lipids were resuspended in 60 μl of chloroform/methanol 2:1 and applied to a TLC plate. Phospholipids were separated using two solvents, composed of petroleum ether/diethyl ether/acetic acid 84:15:1 v/v and chloroform/methanol/acetic acid/water 60:50:1:4 v/v. Development was performed by exposure of the plate to iodine vapour. The spots corresponding to the relevant phospholipids (identified using co-migrating standards) were scraped and counted in a scintillation counter (Packard Tri-Carb 2900TR).

Analysis of phospholipid synthesis in subcellular fractions
-----------------------------------------------------------

Crude mitochondrial fractions were isolated from MEFs as described ([@b3]). Two hundred micrograms were incubated in a final volume of 200 μl of phospholipid synthesis buffer (10 mM CaCl~2~, 25 mM HEPES pH 7.4, and 3 μCi/ml ^3^H-Ser) for 30 min at 37°C. The reaction was stopped by addition of three volumes of chloroform/methanol 2:1. Lipid extraction and TLC analysis were performed as described above.

Assay of ACAT activity
----------------------

To measure ACAT activity *in vivo*, whole cells were incubated in serum-free medium for 2 h to remove all exogenous lipids. After that, 2.5 μCi/ml of ^3^H-cholesterol was added to FBS-free DMEM containing 2% FAF-BSA, allowed to equilibrate for at least 30 min at 37°C, and the radiolabelled medium was added to the cells for the indicated periods of time. Cells were then washed and collected in DPBS, removing a small aliquot for protein quantification. Lipids were extracted as described above and samples were analysed by TLC along with an unlabelled CE standard. A mixture of chloroform/methanol/acetic acid 190:9:1 was used as solvent. Iodine stains corresponding to CE bands were scraped and counted.

Cinnamycin and duramycin assays
-------------------------------

Cinnamycin and duramycin were diluted in FBS-free DMEM to the appropriate concentration and added to the cells for the indicated time periods at 37°C. After incubation, cells were washed in PBS twice before testing cell viability by Live/Dead assay (Invitrogen \#L3224) according to manufacturer\'s instructions. Samples were then analysed under the microscope and cell death was quantified by counting live (green) and dead (red) cells manually. To detect fluorescent cinnamycin with FL-SA-Ro, cells were washed three times with Hanks\' buffered saline containing 0.5% BSA (0.5% BSA--HBS) and incubated with 50 μg/ml Cy3-conjugated cinnamycin (FL-SA-Ro) for 30 min at 37°C. Cells were then washed with 0.5% BSA--HBS and analysed under the microscope. To visualize cell morphology, cells were then counterstained with 5 mM calcein (AnaSpec \#89203) in PBS for 20 min at room temperature, fixed in 4% paraformaldehyde, mounted, and analysed under the microscope.

Analysis of ER--mitochondrial apposition
----------------------------------------

Cells under were co-transfected with GFP-Sec61-β (Addgene plasmid \#15108) and DsRed-Mito (Clontech, \#632421) at a 1:1 ratio, using Lipofectamine 2000 (Invitrogen, \#11668-027) in serum-free DMEM. Twelve hours post transfection, cells were analysed in a single-plane with a Zeiss LSM510 microscope. Interactions between mitochondria and ER were calculated using Image J software (<http://rsbweb.nih.gov/ij/>), determining the area occupied by one organelle and using its signal as a mask for the other one. The various 'colocalization\' data sets were compared using Mander\'s coefficient.

Transmission EM
---------------

Cells were fixed with 2.5% glutaraldehyde in 0.1 M Sorenson\'s phosphate buffer (pH 7.2) for at least 1 h. Cells were then postfixed for 1 h with 1% OsO~4~ in Sorenson\'s buffer. Staining was performed using 1% tannic acid. After dehydration, cells were embedded in a mixture of Lx-112 (Ladd Research Industries) and Embed-812 (EMS, Fort Washington, PA). Thin sections, cut on an MT-7000 ultramicrotome, were stained with uranyl acetate and lead citrate, and examined in a JEOL JEM-1200 EXII electron microscope. Pictures were taken on an ORCA-HR digital camera (Hamamatsu) and recorded with an AMT Image Capture Engine.

Transcriptional silencing
-------------------------

To knockdown mouse *Ps1*, small hairpin (sh) RNA oligonucleotide M2 @ nt 179--197 in mouse *Psen1* (Genbank NM_008943: gacaggtggtggaacaaga) and mismatch control shRNA M3 (gacagg**a**gg**a**ggaacaaga; mismatches in bold) were inserted into pSUPER-Retro-Puro vector pSR (OligoEngine). We also replaced the puromycin-resistance cassette with a blasticidine-resistance cassette inserted at the *Nhe*I-*Dra*III sites in the vector, generating pSR-Blast, to allow for 'double transduction\' using two different selection markers to increase shRNA expression. Viral supernatants (3 ml) from plasmid-transfected Amphotrophic Phoenix ΦNX-A packaging cells supplemented with polybrene were added to immortalized mouse MEFs (derived from primary MEFs of mixed C57Bl/6-129 mice, using a 3T3 subculture schedule; [@b92]), seeded 1 day prior to infection at 100 000/well in 6-well culture plates, followed by infection for 24 h. Cells were selected in medium containing puromycin, blasticidine, or both antibiotics, for 14 days. Using this protocol, PS1 expression was reduced by \>75% ([Supplementary Figure S3](#S1){ref-type="supplementary-material"}). For complementation experiments, human WT PS1 and mutated PS1 (A246E) cloned in pSuper-Retro-Neo and viral supernatants were prepared as described above. Transduced cells were selected using G418.

To knockdown presenilin expression, shRNAs against mouse *Psen1* (Sigma SASI_Mm01_00048853) and *Psen2* (Sigma SASI_Mm02_00310708) and against human *PSEN1* (Sigma SASI_Hs01_00043630) and *PSEN2* (Sigma SASI_Hs01_00033516) were transfected transiently together into relevant mouse and human cells, respectively, according to manufacturer\'s recommendations. Briefly, cells plated at low confluence were transfected with each shRNA to a final concentration of 30 nM, using Lipofectamine 2000 (Invitrogen, 11668-027) at a 1:1 ratio in serum-free DMEM. After 5 h, the medium was changed to 2% FBS DMEM and the cells were incubated for 12 more hours. Successful silencing of the targeted proteins was checked by western blot. To knockdown mouse *Mfn2* in WT and Ps1/2-DKO MEFs, shRNA against *Mfn2* (Sigma SASI_Mm01_00027313) was transfected and analysed in a similar fashion.

Where indicated, cells were transfected with pcDNA3-PS1WT or pcDNA3-PS1D385A mutant (a kind gift of Dr Tae-Wan Kim, Columbia University) at a 1:1 ratio, using Lipofectamine 2000 (Invitrogen \#11668-027) in serum-free DMEM. After 5 h, the medium was changed to DMEM containing 2% FBS. Cells were analysed 12 h post transfection.

Inhibition of γ-secretase activity
----------------------------------

Cells were treated with 2--5 μM DAPT in 2% FBS DMEM, a highly specific γ-secretase inhibitor ([@b61]), for 24 h. Following treatment, the cells were collected in PBS and then analysed, as described.

Quantitative RT--PCR (qRT--PCR)
-------------------------------

Total RNA was extracted from MEFs using TRIzol® Reagent (Invitrogen 15596-018) according to manufacturer\'s instructions, and was quantified by NanoDrop2000 (Thermo Scientific). One microgram of total RNA was used to obtain cDNA by RT--PCR using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems; PN 4368813, 4374966). Real-time PCR was performed in triplicate in a StepOnePlus™ Real-Time PCR System (Applied Biosystems; 4376600). The expression of each gene under study was analysed using specific predesigned TaqMan Probes and normalizing against *Gapdh* expression (Applied Biosystems, 4352339E) as an internal standard.
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![MAM displays the features of a lipid raft. (**A**) Mouse liver Percoll-purified MAM treated with or without TX100 prior to centrifugation through a second Percoll gradient. The low density fraction (arrow) is detergent resistant but solubilizable by methanol (MeOH), implying that it is a DRM. (**B**) Western blot of fractions from a 5--30% sucrose gradient (triangle; lower density at left) of MAM isolated from a Percoll gradient (as in **A**). The pellet (P) denotes TX100-soluble material. (**C**) Western blot of gradient fractions of mouse liver PM and crude mitochondrial extract (CM) to detect Src (PM marker) and Pemt (MAM marker).](emboj2012202f1){#f1}

![Cholesterol metabolism in PS-mutant and AD cells. (**A**) Total cholesterol in the indicated mouse brain fractions (*n*=3, except PM rafts; *n*=2). (**B**) ACAT activity in mouse brain fractions (*n*=4). Inset: western blot to detect ACAT protein; 20 μg protein loaded in each lane. Asterisk denotes significant difference versus ER and mito fractions (*P*\<0.05). (**C**) Content of cholesterol species in PS-mutant MEFs relative to that in WT MEFs (numbers denote average amounts of the indicated cholesterol species, in ng/mg protein). (**D**) ACAT activity (i.e., conversion of ^3^H-cholesterol to ^3^H-cholesteryl esters) in MEFs after 6 h (*n*=6). (**E**) Kinetics of CE synthesis (performed as in **D**) in Ps1-KD cells (note increased slope (line of best fit, in cpm/μg/h) versus control). (**F**) Quantitation of ^3^H-CE synthesis after 6 h in fibroblasts from FAD (*n*=5; 4 PS1 (circles), 1 PS2 (triangle)) and SAD (*n*=9) patients versus paired controls. For cell lines that were evaluated multiple times (see [Supplementary Table S1](#S1){ref-type="supplementary-material"}), the data point represents an average of the assays. Boxes with centred lines denote averages±s.d.; asterisks denote significant difference versus WT (*P*\<0.05).](emboj2012202f2){#f2}

![Detection of lipid droplets in PS-mutant and AD cells. (**A**) EM of DKO MEFs. Note the presence of features reminiscent of lipid droplets (asterisks); these were not observed in WT MEFs. M, mitochondrion. (**B**) Left: LipidTox staining of DKO MEFs; note punctate staining (i.e., lipid droplets) that are absent in WT MEFs. Right: Quantitation of LipidTox staining. (**C**) Left: LipidTox staining of Ps1-KD cells. Right: Quantitation, as in (**B**). Note that overexpression of human WT-PS1, but not A246E mutant PS1, reduced lipid droplet formation. C, mismatched shRNA control. (**D**) Example of LipidTox staining (left) and quantitation of LipidTox-positive fibroblasts from FAD (*n*=7) and SAD (*n*=9; 7 PS1 (circles), 1 PS2 (triangle), 1 APP (square)) patients versus controls (*n*=7) (right). See other examples in [Supplementary Figure S6](#S1){ref-type="supplementary-material"}. Other notation as in [Figure 2](#f2){ref-type="fig"}.](emboj2012202f3){#f3}

![Phospholipid synthesis in PS-mutant and AD cells. (**A**) Synthesis of ^3^H-PtdSer and ^3^H-PtdEtn after labelling DKO MEFs with ^3^H-Ser for the indicated times (h) (*n*=3). (**B**) Pulse-chase. MEFs were labelled for 1 h with ^3^ H-Ser and chased with cold Ser for the indicated times (*n*=3). Note the steeper slopes (i.e., rates of ^3^ H-Ser incorporation) for both PtdSer (negative slopes) and PtdEtn (positive slopes), indicative of a more rapid conversion of PtdSer to PtdEtn, especially in the DKO cells. (**C**) Phospholipid synthesis in crude mitochondria from Ps-KO MEFs (*n*=3 or 4, as indicated; error bars, s.e.). (**D**) Kinetics of PtdSer and PtdEtn synthesis (as in **A**) in Ps1-KD cells. (**E**) Phospholipid synthesis after 6 h (as in **A**) in fibroblasts from FAD (*n*=6) and SAD (*n*=9) patients. Note: three of the SAD PtdEtn values were unusually high (∼600% of control) and were omitted from the statistical analyses. Other notation as in [Figure 2](#f2){ref-type="fig"}.](emboj2012202f4){#f4}

![Cinnamycin sensitivity in PS-mutant and AD cells. (**A**) Left: Example of live/dead assays (1 μM cinnamycin for 10 min at 37°C). Middle: Example of cinnamycin-sensitivity curves in PS-mutant MEFs. Right: Summary of cinnamycin sensitivity assays (1 μM Cin for 10 min) in PS-mutant MEFs. (**B**) Left: Example of cinnamycin sensitivity in Ps1-KD cells versus mismatch control (C). Note that overexpression of human WT PS1, but not A246E mutant PS1, could 'rescue\' Cin sensitivity. Right: Cin/Dura sensitivity in fibroblasts from FAD (*n*=7) and SAD (*n*=8) patients versus controls (*n*=7). (**C**) Left: Example of staining of control and AD patient cells with fluorescent cinnamycin (FL-SA-Ro; orange); cells were counterstained with calcein (green) to visualize overall cell morphology. Right: Quantitation of FL-SA-Ro staining in fibroblasts from FAD (*n*=3) and SAD (*n*=3) patients compared to controls (*n*=3). See other examples in [Supplementary Figure S7](#S1){ref-type="supplementary-material"}. Other notations as in [Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}.](emboj2012202f5){#f5}

![ER--mitochondrial colocalization in Ps-mutant and AD cells. (**A**) Example of confocal images of cells stained with Mito DS Red (red) and GFP-Sec61β (green). In the insets, note the large number of discrete red and green signals in the WT as compared to the Ps-mutant MEFs, which have more overlap (orange and yellow signals). (**B**) Quantitation of colocalization (as in **A**) by Image J in WT (average of 10 images ±s.d.), Ps1-KO (*n*=11), Ps2-KO (*n*=13), and DKO (*n*=7) MEFs (left), and in fibroblasts from FAD (*n*=2) and SAD (*n*=5) patients compared to controls (*n*=3) (right). Other notations as in [Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}.](emboj2012202f6){#f6}

![Electron microscopy of Ps-mutant and AD cells. (**A**, **C**, **E**) DKO MEFs. (**B**, **D**) WT MEFs. Note increased length of regions of contact between ER and mitochondria (M) (arrowheads) in DKO MEFs, and, in (**E**), a region of ER 'sandwiched\' between two mitochondria. (**F**) Quantitation of ER--mitochondrial contact lengths in MEFs (∼40 contacts analysed) and in fibroblasts from AD patients (∼25 contacts). See also [Supplementary Figure S8](#S1){ref-type="supplementary-material"}.](emboj2012202f7){#f7}

![Analysis of MAM function in Mfn2-KO MEFs. (**A**) Kinetics of CE synthesis (performed as in [Figure 2E](#f2){ref-type="fig"}) in Mfn2-KO MEFs (note decreased slope versus control). (**B**) Phospholipid synthesis after 6 h (as in [Figure 4A](#f4){ref-type="fig"}) in Mfn2-KO cells (right) (*n*=3). (**C**) Western blot to detect APP and its C-terminal cleavage products C99 and AICD (cleavage scheme at top) in Ps1/2-DKO and Mfn2-KO MEFs (image at the left is a composite of two non-adjacent lanes from the same gel; vertical dashed line indicates where the two lanes were apposed). Note the absence of AICD in DKO MEFs, and the shift in the ratio of C99:AICD in Mfn2-KO versus WT MEFs. (**D**) Subcellular distribution of presenilins in Mfn2-KO versus WT MEFs. Note that the loss of Mfn2 does not alter the predominant localization of presenilins in MAM. Other notations as in [Figure 2](#f2){ref-type="fig"}.](emboj2012202f8){#f8}

![Rescue of phospholipid (PL) synthesis in Ps- and Mfn2-mutant MEFs. (**A**) Synthesis of ^3^H-PtdSer and ^3^H-PtdEtn after labelling for 6 h with ^3^ H-Ser in the indicated MEFs. Left: Note that PL synthesis was *decreased* in Mfn2-KO MEFs compared to WT but was restored upon knockdown of *Ps1*+*Ps2* (average of four experiments ±s.e.). A control knockdown of *Ps1*+*Ps2* in WT MEFs increased PL synthesis, as expected (not shown). Right: In the converse experiment, note that PL synthesis was *increased* in Ps1+Ps2 DKO MEFs compared to WT but was restored upon knockdown of *Mfn2* (average of five experiments ±s.e.). A control knockdown of *Mfn2* in WT MEFs reduced PL synthesis, as expected (not shown). (**B**) Examples (as in [Figure 6A](#f6){ref-type="fig"}), and quantitation (average of 20 cells analysed ±s.e.), of ER--mitochondrial contacts in WT, Ps1+Ps2-DKO, and DKO cells 'rescued\' by knockdown of *Mfn2*. (**C**) Effect of presenilins and Mfn2 on duramycin sensitivity. Note that Dura sensitivity correlates with the change in PtdEtn synthesis shown in (**A**). (**D**) Quantitation of lipid droplets in *Ps1+Ps2* DKO MEFs upon knockdown of *Mfn2* (average of five images ±s.e.). Other notation as in [Figure 2](#f2){ref-type="fig"}.](emboj2012202f9){#f9}

![MAM function in cells deficient in γ-secretase activity. (**A**) Detection of lipid droplets in HeLa and 3T3 cells treated with 5 μM DAPT for 24 h. Examples of LipidTox staining (left) and quantitation (right; *n*=number of images analysed, with a total of ∼500 cells analysed ±s.e.), as in [Figure 3](#f3){ref-type="fig"}. Note the large increase in LipidTox staining, ranging from ∼200 to ∼700% over control. (**B**) Phospholipid transport in the indicated cells (as in [Figure 4](#f4){ref-type="fig"}). Note the modest increase in PtdSer and PtdEtn synthesis, of only ∼20%. (**C**) Colocalization of ER and mitochondria (as in [Figure 6](#f6){ref-type="fig"}) in HeLa cells. Note that DAPT had no effect on the degree of colocalization. Other notation as in [Figure 2](#f2){ref-type="fig"}.](emboj2012202f10){#f10}

![A model of pathogenesis of Alzheimer disease. In broad view, underlying genotypes that either cause AD directly (in the case of FAD) or are risk factors that predispose to developing AD (in the case of SAD) increase MAM function and/or ER--mitochondrial communication. This increase affects various MAM-mediated processes (either positively or negatively, depending on the particular gene/function involved), which in turn give rise to the various phenotypes seen in AD. See text for details.](emboj2012202f11){#f11}
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